(Q34553446)

English

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

V Ballova

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

J-U Rüffer

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

H Haverkamp

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

B Pfistner

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

H K Müller-Hermelink

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

E Dühmke

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

P Worst

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Wilhelmy

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

R Naumann

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Hentrich

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

H T Eich

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A Josting

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Löffler

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

V Diehl

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A Engert

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

124-131

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Age and Hodgkin's disease: the impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Hodgkin's disease in elderly patients (> or =60): clinical outcome and treatment strategies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

The prognosis of Hodgkin's disease in older adults

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 t

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Hodgkin's disease in the elderly: a retrospective clinicopathologic study of 61 patients aged over 60 years

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI023

21 January 2018

Identifiers

10.1093/ANNONC/MDI023

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34553446&oldid=1977993030"